



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Complete if Known

Application Number	10/529,115
Filing Date	March 24, 2005
First Named Inventor	Brian G. Condie
Art Unit	
Examiner Name	
Attorney Docket Number	18377-0059

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). www.uspto.gov See Kind's Codes of USPTO Patent Document at www.uspto.gov or MPEP 901.04.
Error: Office that issued the document, by the two-letter code (WFO Standard S1.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the year of the common era. For example, the year 1999 is indicated as Heisei 11. If the year of the reign of the Emperor is not indicated, the year of the common era must be marked here. If English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is the fee (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form, and suggestions for reducing this burden, should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22314-1450. DO NOT WRITE IN THESE SPACES.
SEND FEES OR COMPLETE FORMS TO THIS ADDRESS: SEND TO: COMMISSIONER OF PATENTS AND TRADEMARKS, U.S. DEPARTMENT OF COMMERCE, WASHINGTON, DC 20514-0001
 If you need assistance in completing the form, call 1-800-PTO-9191 (1-800-756-8181) and TDD 1-800-451-5267.

Substitute for form 1449/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	2	of	3
-------	---	----	---

Application Number	10/529,115
Filing Date	March 24, 2005
First Named Inventor	Brian G. Condie
Art Unit	
Examiner Name	
Attorney Docket Number	18377-0059

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the articles (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BAIN, et al., 1995, "Embryonic Stem Cells Express Neuronal Properties <i>in vitro</i> ," <i>Dev. Biology</i> , 168:342-357.	
		BIEBERICH, et al., 2001, "Regulation of Apoptosis During Neuronal Differentiation by Ceramide and b-Series Complex Gangliosides," <i>The Journal of Biological Chemistry</i> , 276:44396-44404.	
		BIEBERICH, et al., 1999, "Differential Effects of Glycolipid Biosynthesis Inhibitors on Ceramide-Induced Cell Death in Neuroblastoma Cells," <i>Journal of Neurochemistry</i> , 72:1040-1049.	
		BLASCHKE, et al., 1998, "Programmed Cell Death is a Universal Feature of Embryonic and Postnatal Neuroproliferative Regions throughout the Central Nervous System," <i>The Journal of Comparative Neurology</i> , 396:39-50.	
		BLASCHKE, et al., 1996, "Widespread Programmed Cell Death in Proliferative and Postmitotic Regions of the Fetal Cerebral Cortex," <i>Development</i> , 122:1165-1174.	
		BRUGG, et al., 1996, "Ceramide Induces Apoptosis in Cultured Mesencephalic Neurons," <i>Journal of Neurochemistry</i> , 66:733-739.	
		BRUSTLE, et al., 1997, "In Vitro-Generated Neural Precursors Participate in Mammalian Brain Development," <i>Proc. Natl. Acad. Sci. USA</i> , 94:14809-14814.	
		CARPENTER, et al., 2001, "Enrichment of Neurons and Neural Precursors from Human Embryonic Stem Cells," <i>Exper. Neuro.</i> , 172:383-397.	
		CASACCIA-BONNEFIL, et al., 1996, "Death of Oligodendrocytes Mediated by the Interaction of Nerve Growth Factor with its Receptor p75," <i>Nature</i> , 383:716-719.	
		CHUN, Jerold, 2000, "Cell Death, DNA Breaks and Possible Rearrangements: An Alternative View," <i>Trends in Neuroscience</i> , 23:407-408.	
		DECREANE, et al., 2002, "Identification of Genes Involved in Ceramide-Dependent Neuronal Apoptosis using cDNA Arrays," <i>Genome Biol.</i> , 3(8):research 0042.1-0042.22.	
		ESDAR, et al., 2001, "Differentiation-Associated Apoptosis of Neural Stem Cells is Effected by Bcl-2 Overexpression: Impact on Cell Lineage Determination," <i>Eur. J. Cell Biol.</i> , 80:539-553.	
		FRACHARD, et al., 1995, "In Vitro Differentiation of Embryonic Stem Cells into Glial Cells and Functional Neurons," <i>J. Cell Sci.</i> , 108:3181-3193.	
		FURUYA, et al., 1998, "Ceramide and Its Interconvertible Metabolite Sphingosine Function as Indispensable Lipid Factors Involved in Survival and Dendritic Differentiation of Cerebellar Purkinje Cells," <i>Journal of Neurochemistry</i> , 71:366-377.	
		HARTFIELD, et al., 1997, "Ceramide Induces Apoptosis in PC12 cells," <i>FEBS Letters</i> , 401:148-152.	
		HERGET, et al., 2000, "Production of Ceramides Causes Apoptosis During Early Neural Differentiation <i>In Vitro</i> ," <i>The Journal of Biological Chemistry</i> , 275:30344-30354.	
		IRIE, et al., 1998, "Application of Exogenous Ceramide to Cultured Rat Spinal Motoneurons Promotes Survival or Death by Regulation of Apoptosis Depending on its Concentrations," <i>Journal of Neuroscience Research</i> , 54:475-485.	
		ITO, et al., 1995, "Ceramide Prevents Neuronal Programmed Cell Death Induced by Nerve Growth Factor Deprivation," <i>Journal of Neurochemistry</i> , 65:463-466.	
		JAFFREZOU, et al., 1998, "Positive Feedback Control of Neural Sphingomyelinase Activity by Ceramide," <i>FASEB</i> , 12:999-1006.	
		KAWASAKI, et al., 2002, "Generation of Dopaminergic Neurons and Pigmented Epithelia from Primate ES Cells by Stromal Cell-Derived Inducing Activity," <i>Proc. Natl. Acad. Sci. USA</i> , 99(3):1580-1585.	
		KAWASAKI, et al., 2000, "Induction of Midbrain Dopaminergic Neurons from ES Cells by Stromal Cell-Derived Inducing Activity," <i>Neuron</i> , 28:31-40.	
		KIM, et al., 2002, "Dopamine Neurons Derived from Embryonic Stem Cells Function in an Animal Model of Parkinson's Disease," <i>Nature</i> 418:50-56.	
		LI, et al., 1998, "Generation of Purified Neural Precursors from Embryonic Stem Cells by Lineage Selection," <i>Current Biol.</i> 8:871-874.	
		LIU, et al., 2000, "Hypoxic Preconditioning Protects Cultured Neurons against Hypoxic stress via TNF- α and Ceramide," <i>Am. J. Physiol. Cell Physiol.</i> , 278:C144-C153.	
Examiner Signature	/Daniel Gamett/ (01/03/2008)		Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Date
Considered

*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including reviewing, preparing, and submitting the information to the USPTO. Time necessary depending upon the individual case. Any comments on the amount of time you require to complete this form or for suggestions for reducing this burden, should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.